ArticleScientific reports2025
Design, synthesis and medical prospects of electrospun molecularly imprinted fibers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study describes fabrication of molecularly imprinted (MI) electrospun nanofibers of average diameter 500 nm for controlled delivery of two templates; ferulic acid (FA) and khellin. Polycaprolactone (PCL) was used as supporting matrix in fiber preparation while polyallylamine (PAM) was added to provide molecular recognition sites for the template. The preparation of MI fibers was optimized using design of experiments (DoE). For FA fibers, a fractional factorial deign was used to screen different factors involved in the electrospinning process and it was found that FA and PAM concentration; in addition to PCL concentration were significant. These two variables were used to create a central composite design to optimize fiber diameter. Control fibers were prepared by directly loading ferulic acid into the fiber matrix without PAM. In vitro release studies revealed that MI fibers had more controlled release of FA compared to control fibers. DoE were also used to optimize the diameter of khellin MI fibers. In vitro release studies for khellin MI fibers did not show any significant difference when compared to control fibers. MTT assay was conducted to assess the cytotoxicity of MI fibers against mouse melanoma B16F10 cell lines. FA fibers were well-tolerated by the cells up to a concentration of 250 µg/ml, while khellin fibers showed no cytotoxicity up to a concentration of 125 µg/ml. On the other hand, the non-medicated fibers prepared with only PCL/PAM were safe up to 500 µg/ml, suggesting that the cytotoxicity observed at higher concentration of the MI fibers is due to the effect of FA or khellin. The MI fibers were then subjected to ex-vivo skin permeation studies using vertical Franz diffusion cell with Sprague Dawley male rats back skin. After 24 h, the percentage of permeated drug was 12.71 ± 0.05% for FA and 22.99 ± 0.04% for Khellin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.